Trial To Study Targeted Antiangiogenesis Drug Sutent And Radiation Against Cancer

Last year, the drug Sutent (sunitinib) made headlines for its effectiveness against kidney and gastrointestinal cancers.

Now, radiation oncologist at the Kimmel Cancer Center at Jefferson in Philadelphia are hoping to find out if combining Sutent and radiation will help patients with a wide range of cancers.

Adam P. Dicker, M.D., Ph.D., professor of radiation oncology at Jefferson Medical College of Thomas Jefferson University, and his co-workers are enrolling patients in a Phase 1 clinical trial aimed at looking for potential side effects in patients receiving small amounts of the combination treatment for a variety of cancers, such as brain tumors and prostate, lung, and head and neck cancers.